Great. Thank you, Martin. And I want to thank Xbrane Biopharma and STADA for the partnership and for inviting me to join today. Valorum Biologics was really founded on the principle to provide value to markets that are currently underserved. Despite 45 biosimilars approved in the US, there remains a significant opportunity within the marketplace. What I'll be reviewing today is our team, our focus, the US landscape, and specifically how we view the anti-VEGF market within ophthalmology. Our team is very privileged to have a seasoned group of professionals join us on this venture. As you can see, very large pharma experience, quite a bit of experience launching multi-billion dollar brands in the marketplace, as well as developing them from preclinical all the way to global phase three and then eventual approval, as you can see with J&J, Merck, Genentech, Roche across the slide deck. We also have recent biosimilar experience, particularly with our regulatory team and our manufacturing team, namely with Coherus' recent approvals, and also in manufacturing commercial supply as well. Coupled with our extensive management team and our broad pharma experience, we are very pleased to have what we believe is a very unique combination of large pharma experience. Added to this is large distribution experience. As you can see, we have past presidents from AmerisourceBergen, McKesson, and Cardinal Health. Mark Santos, Mike Cunningham, Joe DePinto have literally built some of the largest distribution and specialty networks here within the US. If you're familiar with US commercialization, over 97% of all drugs sold within the US fall somewhere within those big three umbrellas. Either it's their specialty wholesaler or to specialty pharmacies. So we have the unique convergence of big pharma and distribution to guide our strategies and to basically optimize our pipeline as we look at new assets to bring in, coupled with the big pharma and distribution expertise, we have Wall Street executives that have helped co-found the company, Tim Opler, who is a partner and co-founder in Valorum, but also was a partner and co-founder in Trade Partners and investment bank in New York, which was then sold to Stifel Financial. Tim is a serial entrepreneur and has started dozens of companies himself, raising over $1 billion in the public markets. David Barrett is also a Wall Street executive, that has raised multi-billion dollars over his career and started a number of companies with several successful exits. And both are guiding our financial efforts with fundraising, etc. Our focus is clear with our first few assets, namely in the US, we are focused on regulatory approval to get to commercial. We are going to, from our first few commercial assets, build significant P&L, which will offer us the opportunity to add additional programs and become a market leader. And as I mentioned, within the US, there remains a major, significant unmet need across the existing markets that have biosimilars approved, and most importantly, across markets that have not seen biosimilar entry yet. The next slide is a nice schema from a recent report presented by Activia. In the US, you have $260 billion worth of biologic market opportunity. Currently, the top bolded middle square shows you the opportunity that is currently facing biosimilar competition, about 40 billion or so at the time of this publication that represented 12 molecules. Currently, we have 14 molecules that have biosimilar competition. And of the most mature markets in the US, the oncology space sits prominently. Currently, just a handful of commercial parties are commercializing within that market segment where we see significant opportunity for multiple entrants given the time of entry. But most importantly, the middle bar here represents almost $200 billion worth of future biosimilar competition, approximately half of that market is being addressed by current developers today, where we see Valorum literally sitting in the middle of that is we have the opportunity to take advantage of markets that are commercially ready today, build our PNL. But aspirationally, we really look forward to providing value in developing and partnering with global partners to bring biosimilars into the US, where markets are currently not being served. I've had the privilege of speaking to many colleagues who treat patients within some of these segments. These biologics have transformed the way these patients are treated today. But in many cases, it's been decades since they've seen any price relief. And we look forward to providing that value in the future through our organization and through our partnerships that we will create globally. In addition to the market opportunity, the US dynamics are changing quite significantly. Since our first biosimilar approvals, the FDA has moved significantly and advanced its learnings of biosimilars from a regulatory approval perspective. But also, as recently as just a month ago, had leveled the playing field, and the FDA had called on Congress to eliminate the interchangeable designation that was originally provided. Now, what this does is basically provide interchangeability to all biosimilars that are approved. Once approved in the US, all can be interchangeable, given their safety, efficacy, and more importantly, their bioequivalence to the reference product. In addition to the regulatory tailwinds, we are also seeing legislative updates that provide more incentives to biosimilar usage. Despite your political preference, all parties want to reduce healthcare costs within the IRA. The incentive has been increased for biosimilars. So for qualifying biosimilars, they can be reimbursed at a higher rate than the reference product. Once that has been achieved, that can be maintained for a five-year period. So the perspective here, one, the US market is large. And significant opportunity remains within the commercial markets today. But most importantly for tomorrow, the regulatory and legislative changes are supporting new entrants and provide a fruitful opportunity to bring biosimilars into the US. Our pipeline, led by the partnership with Xbrane and STADA. Has a tremendous opportunity to provide value in the near term. We do see Valorum as a multi-asset program with significant opportunities to launch multiple assets over a ten-year business model. Our second asset is rounding phase three as we speak and positions ourselves for a nice multi-asset launch over the years to come. We have several other programs that we are talking to global parties with, that are at various stages of development and various stages of diligence. And look forward to adding to this slide here in the near future. So, specifically within the anti-VEGF market opportunity. In the US, we have seen a number of launches lately. Random buzz about biosimilars has made its first entry within the ophthalmology space. Bisimol from Roche is definitely making some strong inroads with the bispecific approach. High-dose Eylea from Regeneron has also been recently launched within the year. Despite all of the entries, you can clearly see a tremendous opportunity for growth year over year. Global data projects this market, given the aging population and other dynamics, to significantly grow, surpassing $20 billion in sales by 2030. We've also noted some of our competitors on the Eylea biosimilar front have faced patent challenges, which may provide opportunities for another biosimilar to provide value not only in the Lucentis space but potentially moving into other market opportunities as well across the anti-VEGF market opportunity in the US. The market is big and is growing. A percent of this market today will be a very big value as the market increases over time. Specifically within the biosimilar opportunity. We do see a really nice case example from Coherus. They recently launched their biosimilar and as you can see, really started to ramp up sales, particularly in the last few quarters. The big jump here from Q1 2023 to Q2 2023 was the addition of the reimbursement code that provides US providers certainty of reimbursement, efficiency of submitting that reimbursement claim. Before that, they were dealing with a miscellaneous code, that is cumbersome and offers some delay in reimbursement. Once that reimbursement code was established, they were able to maximize the value of the biosimilar and the commercial opportunity. We see that it has created a significant opportunity in the quarters following the reimbursement code. We see this as a very good signal and a path forward for another entrant. We are clearly not the only folks that like a biosimilar. As you can see, earlier in the year, Sandoz, who recently spun off from Novartis, had purchased that asset from Coherus. As Coherus was shifting focus into its core businesses and moving specifically into oncology, for $170 million up front. It's interesting to note that the $170 million acquisition was for less than 50% of the gross profits. As Coherus was licensing that program, they were paying royalties north of 50%. So, a reasonable biosimilar has shown to be effective, demonstrated penetration in the anti-VEGF space within the ophthalmology market, and clearly has shown a lot of value, attracting attention. And we feel this path forward, in these examples give us strong confidence for commercial uptake for newcomers in the US. Clearly, the market opportunity will support a third entrant. So with that, Martin, I think I've got one more slide with the summary. Yeah. Great. So to summarize the brief overview that we provided: experienced and dedicated team to focus on the launch in the US. Clearly, given the market opportunity within the US, it can support an additional random amount of biosimilar. Together, all three entities—Xbrane, STADA, and Valorum—we believe create an optimal partnership to secure FDA approval and the eventual launch of the company in the US. And look forward to taking questions.